Defective viruses are viral particles with genetic abnormalities or mutations that render them unable to complete their life cycle or replicate efficiently. These viruses often lack essential genes required for replication or exhibit structural defects in their genetic material. Defective viruses may arise naturally during the course of viral infections or can be intentionally engineered for therapeutic purposes. In some cases, defective viruses can interfere with the replication of their fully functional counterparts through a phenomenon known as viral interference. This interference may limit the spread of the functional virus and impact the severity of the infection. Defective viruses have been studied in the context of oncolytic virotherapy, where they are designed to selectively infect and destroy cancer cells while sparing normal cells. These engineered defective viruses can replicate in cancer cells, leading to their destruction, and may be used as potential treatments for certain types of cancers. Understanding defective viruses provides insights into viral evolution, host-virus interactions, and the development of novel therapeutic strategies for both infectious diseases and cancer. Ongoing research in this field aims to harness the potential of defective viruses for targeted and innovative medical interventions.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States